Yuhan Corporation (000100) announced that it has signed an active pharmaceutical ingredient (API) supply contract worth 131,074,406,400 won with a global pharmaceutical company.

The contract value is USD 95,424,000 (95 million dollars), equivalent to 131,074,406,400 won when converted to Korean currency. This represents 6.0% of the company's most recent consolidated revenue (2,186,637,586,358 won) based on the 2025 consolidated financial statements. The won conversion was calculated using the initial announced exchange rate of 1,373.60 won per dollar as of September 1.

The contract counterparty is a global pharmaceutical company. At the counterparty's request, the company name was not disclosed for reasons of business confidentiality. Yuhan plans to disclose the name of the contract counterparty once grounds for lifting the disclosure exemption arise, with the disclosure exemption deadline set until May 31, 2028.

The contract period runs from September 1, 2026 to May 31, 2028. However, the contract end date may change by mutual agreement between the two parties. The sales and supply regions are yet to be determined, and there is no down payment or advance payment. The contract date is September 1, the date the purchase order was received.

Meanwhile, Yuhan's stock closed at 82,700 won on the Korea Exchange (KRX) on the 1st, down 1.19%.

[This article is by no means an investment recommendation. The content may merely reflect opinions, so please do not use it as a reference or material for investment. All investments are made at each individual's own discretion, and the final responsibility lies with the investor. This publication assumes no responsibility whatsoever.]